Paroxysmal nocturnal hemoglobinuria laboratory findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Categories) |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ Paroxysmal nocturnal hemoglobinuria }} | {{ Paroxysmal nocturnal hemoglobinuria }} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
* PNH can present with or as other disease entities such as aplastic anemia or myelodysplasia (MDS). Patients who present with pancytopenia or thrombosis compounding anemia should be suspected of having PNH. Many patients with bone marrow failure ([[aplastic anemia]]) develop [[PNH]](10-33%). Aplastic anemia can be caused by an attack by the immune system against the bone marrow. For this reason, drugs that suppress the immune system are being researched as a therapy for PNH.<ref>Sacher, Ronald A. and Richard A. McPherson. "Wildman's Clinical Interpretation of Laboratory Tests, 11th edition."</ref> <ref>Kumar, Vinay, Abu Abbas, and Nelson Fausto. "Robbins and Cotran Pathologic Basis of Disease, 7th edition."</ref> A small percentage of PNH patients can have dysplasia that leads to Acute Myelocytic Leukemia. Interestingly, the blasts of the PNH-derived AML also lack leukocyte alkaline phosphatase (LAP) and decay accelerating factor (CD59;DAF). | * PNH can present with or as other disease entities such as aplastic anemia or myelodysplasia (MDS). Patients who present with pancytopenia or thrombosis compounding anemia should be suspected of having PNH. Many patients with bone marrow failure ([[aplastic anemia]]) develop [[PNH]](10-33%). Aplastic anemia can be caused by an attack by the immune system against the bone marrow. For this reason, drugs that suppress the immune system are being researched as a therapy for PNH.<ref>Sacher, Ronald A. and Richard A. McPherson. "Wildman's Clinical Interpretation of Laboratory Tests, 11th edition."</ref> <ref>Kumar, Vinay, Abu Abbas, and Nelson Fausto. "Robbins and Cotran Pathologic Basis of Disease, 7th edition."</ref> A small percentage of PNH patients can have dysplasia that leads to Acute Myelocytic Leukemia. Interestingly, the blasts of the PNH-derived AML also lack leukocyte alkaline phosphatase (LAP) and decay accelerating factor (CD59;DAF). | ||
| Line 13: | Line 13: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category: | [[Category:Rheumatology]] | ||
[[Category:Mature chapter]] | [[Category:Mature chapter]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 13:18, 16 June 2016
|
Paroxysmal nocturnal hemoglobinuria Microchapters |
|
Differentiating Paroxysmal nocturnal hemoglobinuria from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Paroxysmal nocturnal hemoglobinuria laboratory findings On the Web |
|
American Roentgen Ray Society Images of Paroxysmal nocturnal hemoglobinuria laboratory findings |
|
FDA on Paroxysmal nocturnal hemoglobinuria laboratory findings |
|
CDC on Paroxysmal nocturnal hemoglobinuria laboratory findings |
|
Paroxysmal nocturnal hemoglobinuria laboratory findings in the news |
|
Blogs on Paroxysmal nocturnal hemoglobinuria laboratory findings |
|
Directions to Hospitals Treating Paroxysmal nocturnal hemoglobinuria |
|
Risk calculators and risk factors for Paroxysmal nocturnal hemoglobinuria laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Laboratory Findings
- PNH can present with or as other disease entities such as aplastic anemia or myelodysplasia (MDS). Patients who present with pancytopenia or thrombosis compounding anemia should be suspected of having PNH. Many patients with bone marrow failure (aplastic anemia) develop PNH(10-33%). Aplastic anemia can be caused by an attack by the immune system against the bone marrow. For this reason, drugs that suppress the immune system are being researched as a therapy for PNH.[1] [2] A small percentage of PNH patients can have dysplasia that leads to Acute Myelocytic Leukemia. Interestingly, the blasts of the PNH-derived AML also lack leukocyte alkaline phosphatase (LAP) and decay accelerating factor (CD59;DAF).
- Ham's acid hemolysis test: A sugar or sucrose lysis test, in which a patient's red blood cells are placed in low ionic strength solution and observed for hemolysis, is used for screening. A more specific test for PNH, called Ham's acid hemolysis test, is performed if the sugar test is positive for hemolysis.[3] In a positive sucrose lysis test ionic strength facilitates the complement binding whereas in a positive Ham acid hemolysis test acidic strength facilitates the complement binding. The differential diagnosis of a positive sugar lysis test includes some autoimmune hemolytic anemias; even leukemias can give a false positive result. The differential diagnosis for a positive Ham test includes congenital dyserythropoietic anemia; note that a negative Ham test doesn't rule out PNH. These assays do not reliably quantitate the percentage of PNH cells and can be falsely negative in patients who have received red blood cell transfusions. Occasionally the characteristic complement-sensitive erythrocytes cannot be demonstrated in patients with well-established PNH. This probably occurs when the production of PNH cells is relatively low and most of the PNH cells that have been made have already been destroyed either in the marrow or in the circulation. Therefore a single normal sucrose hemolysis test cannot be considered absolute evidence that a patient does not have PNH.
References
- ↑ Sacher, Ronald A. and Richard A. McPherson. "Wildman's Clinical Interpretation of Laboratory Tests, 11th edition."
- ↑ Kumar, Vinay, Abu Abbas, and Nelson Fausto. "Robbins and Cotran Pathologic Basis of Disease, 7th edition."
- ↑ Ham TH. Chronic haemolytic anaemia with paroxysmal nocturnal haemoglobinuria: study of the mechanism of haemolysis in relation to acid-base equilibrium. N Engl J Med 1937;217:915-918.